Cell therapies and cell secretome compositions are utilized in the methods of treatment of cardiac injury. The compositions mediate myocardial homeostasis and cardiac wound healing process post-MI via the direct modulation of regulatory T cell (Treg) population dynamics and function.

Cell therapies and cell secretome compositions are utilized in the methods of treatment of cardiac injury. The compositions mediate myocardial homeostasis and cardiac wound healing process post-MI via the direct modulation of regulatory T cell (Treg) population dynamics and function.

In one embodiment, a method includes, by each of one or more network nodes of a multi-hop wireless network that are configured as initiators: receiving from a central controller an address of a particular network node that is configured as a responder. Using the address and by adjusting beamforming weights, the initiator may transmit a message to establish a wireless connection with a particular network node that is configured as a responder. Each responder may adjust its beamforming to receive a message from one of the initiators addressed to the responder to establish a wireless connection with the responder. When the responder receives the message from the initiator addressed to the responder, the responder may respond to the initiator to establish a wireless connection with the initiator.

The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

Mutants of recombinant immunoregulatory protein of Ganoderma lucidum (rLZ-8) and applications thereof are provided. It is found by the present invention that: an anti-EGFR (epidermal growth factor receptor) domain exists in a structure of the rLZ-8; particularly, the domain through positive potential characteristics thereof induces a killing effect to an abnormal EGFR-expressed tumor. Based on the above scientific discovery, with utilizing computational simulation technology, the mutants of the rLZ-8, having better antitumor effects, are obtained.

The present invention relates to a use of insulin-like growth factor binding protein 2 in a preparation of drugs for treating neurological demyelinating diseases. IGFBP2 intervention can significantly increase myelination levels and improve psychiatric symptoms caused by stress demyelination.

This invention provides modified IGFBP-derived peptidescollectively termed immodulator peptidesand related compositions and methods. Chemical modifications to peptides using small molecules, and sequence extensions to immodulator core sequences exhibit new and surprising biological activities. The invention builds the combinatorial power of the immodulator peptide class further by demonstrating which core sequences bind metal or glycosaminoglycans such as heparin. The invention discloses some surprising biological properties of compositions derived from these modifications, including a host of new therapeutic and diagnostic utilities (e.g. immune modulation of TLR signaling, enhanced collagen synthesis by skin fibroblasts, and synergy with a RIG-I agonist in killing melanoma cells). The invention also teaches methods for enhancing previously disclosed uses of immodulator peptides by showing how the modifications of the invention can boost the efficacy of immodulator peptides in a model of burn trauma.

The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.

The present invention provides, among other things, methods and compositions for treating Chronic Lung Disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1) or an agonist or an analog thereof.

A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (g/ml) to about 40 g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations.